A Single-Arm Phase II Study of Isatuximab With Carfilzomib and Pomalidomide in Relapsed or Refractory Multiple Myeloma
Latest Information Update: 20 Dec 2023
At a glance
- Drugs Carfilzomib (Primary) ; Isatuximab (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 07 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 27 May 2022 Status changed from not yet recruiting to recruiting.
- 11 Mar 2022 Planned primary completion date changed from 25 Feb 2026 to 15 Apr 2026.